Abstract: Health needs are common in people living with intellectual disabilities, but we do not know how they contribute to life expectancy. We used the Clinical Practice Research Datalink (CPRD) linked with hospital/mortality data in England (2017–2019) to explore life expectancy among people with or without intellectual disabilities, indicated by the presence or absence, respectively, of: epilepsy; incontinence; severe visual loss; severe visual impairment; severe mobility difficulties; cerebral palsy and PEG feeding. Life expectancy and 95% confidence intervals were compared using flexible parametric methods. At baseline, 46.4% (total \( n = 7794 \)) of individuals with intellectual disabilities compared with 9.7% (total \( n = 176,807 \)) in the comparison group had \( \geq 1 \) health need. Epilepsy was the most common health need (18.7% vs. 1.1%). All health needs except hearing impairment were associated with shorter life expectancy: PEG feeding and mobility difficulties were associated with the greatest loss in life years (65–68% and 41–44%, respectively). Differential life expectancy attenuated but remained (\( \approx 12\% \) life years lost) even after restricting the population to those without health needs (additional years expected to live at 10 years: 65.5 [60.3, 71.1] vs. 74.3 [73.8, 74.7]). We conclude that health needs play a significant role but do not explain all of the differential life expectancy experienced by people with intellectual disabilities.

Keywords: intellectual disability; life expectancy; health needs; epilepsy; incontinence; visual; hearing; mobility; cerebral palsy; PEG feeding

1. Introduction

Addressing the burden of health inequalities is now a global priority [1–3]. Strategies to reduce these inequalities tend to focus on the most vulnerable, such as people living with disabilities or in areas of social deprivation [4–8]. Particularly at risk are those with intellectual disabilities (also known as learning disabilities in the UK) owing to a combination of genetic, social and behavioural factors [9,10]. Whilst there are measures in place to reduce health inequalities in this population, such as annual health checks [11], mortality data suggest that the situation has not improved, despite some deaths being potentially avoidable [12–14].

One of the challenges to reducing inequalities among people living with intellectual disabilities is that they are more likely than the general population to have severe health needs, including epilepsy, cerebral palsy and eating/feedings difficulties, which are known to shorten life expectancy [15]. Although not always life-limiting if managed well, they are
relatively rare in the general population and so tend not to feature in population-level policy initiatives. Thus far, their individual contribution to life expectancy has not been formally investigated, but it is important to do so because this contribution may be over-inflated or seen as an inevitable consequence of having intellectual disabilities without seeking to improve health outcomes and/or quality of life for the individuals affected.

The aim of the current study was to investigate specific health needs and quantify their contribution to life expectancy in people with intellectual disabilities and to compare these findings with a cohort of individuals without intellectual disabilities. A further aim was to investigate people without any of the specified health needs to determine if loss in life years for people with intellectual disabilities remained.

2. Materials and Methods

2.1. Data Sources

This study followed the Reporting of studies Conducted using Observational Routinely-collected health Data (RECORD) checklist [16] (see Supplementary Table S1). We used the Clinical Practice Research Datalink (CPRD GOLD), linked (person-level) with hospital episode statistics (HES) and death registrations from the Office for National Statistics (approved study protocol number 19_267). Details of the study population have been described in a previous work [12], with the exception of 23 additional individuals identified, after an amendment to the original protocol, with Cockayne and Angelman syndrome; details of these 23 individuals were received in August 2021 (due to COVID-19 delays; please see the data flow diagram in Supplementary Figure S1 for the initial extract and the study population used for the current study). Briefly, the CPRD is an electronic health record primary care research database which is broadly representative of the national population in terms of age, gender and ethnicity [17]. Only GP surgeries in England that consented to their data being linked with hospital episode statistics (HES) and death data (approximately 75% of CPRD surgeries in England) were included in this study.

2.2. Sample Population

Initial inclusion criteria for the broader programme of work on which this study was based were: registered at the GP surgery at any point between 1 January 2000 and 29 September 2019 and 10 years old or older to account for delays in reporting of diagnoses of intellectual disability in children [18]. A random sample of 980,586 people without intellectual disabilities (initially 1 million prior to exclusions; see Supplementary Figure S1) was used for the comparison group with the same eligibility criteria (but without a diagnosis of intellectual disability). For this study, data were further restricted to the 2017–2019 observation period such that people entered the study on 1 January 2017 if this was after the original date of cohort entry or were excluded if they were last seen or died before this date. The final population comprised 7794 individuals with intellectual disabilities and 176,807 individuals without intellectual disabilities ($n = 440$ of whom changed status within the observation window at their first intellectual disability diagnosis).

2.3. Definition of Intellectual Disabilities and Health Needs

Diagnostic codes (Read codes and International Classification of Diseases (ICD)-10 codes) for intellectual disabilities and health needs are reported in the Supplementary Material (Table S2). These were based on a combination of previous literature [12], free text searching of diagnostic code descriptions and clinical opinion (RK, SKG, RM). The initial choice of health needs was based on the literature in this area [19] and discussions with carers and people living with intellectual disabilities as being sufficiently severe to affect life expectancy. These were: epilepsy; incontinence (urinary or faecal); severe visual loss; severe hearing impairment; severe mobility difficulties; cerebral palsy and feeding via a percutaneous endoscopic gastrostomy (PEG) tube (i.e., as a measure of severe eating/feeding difficulties). To avoid inclusion of shorter-term health needs that had resolved over time and/or been misdiagnosed in childhood, such as epilepsy [20,21], health needs...
were defined as being present only if their most recent diagnosis was within 10 years of cohort entry. The exception to this was cerebral palsy, which was defined by a diagnosis ever being present given that it is a life-long condition from birth/early infancy [22].

2.4. Statistical Methods

The date of entry into the cohort was defined as the latest date according to the person and practice’s characteristics: the beginning (i.e., 1 January 2017) of the observation window; the date of registration with the GP practice; the date the practice was defined as being up to standard (using the CPRD’s own quality indicators); or the date the individual turned 10 years old (to align with the eligibility criteria). Because there are known delays in reporting intellectual disability diagnoses [23] and to avoid conditioning on the future, an intellectual disability status was treated as an age-dependent covariate such that people with intellectual disabilities contributed to the comparison cohort prior to their first diagnosis. Health needs were also treated as age dependent, and individuals contributed to both the presence and absence of health need at different ages if they were diagnosed with a new health need during the observation period. The date of exit was defined as: the date of the last CPRD update (29 September 2019); the date of death; the date of the end of the calendar period; the date of the last practice update or the date of transfer out of practice, whichever was first. The cohort was also sub-divided into individuals without any health needs at baseline or follow-up to assess whether life expectancy was similar between people with and without intellectual disabilities (i.e., excess mortality could be explained by the health needs).

The methodology for the life expectancy work used in this study has been described in detail elsewhere [24]. Life expectancy and 95% confidence intervals (CIs) were compared for people with and without intellectual disabilities and by the presence/absence of each health need using flexible parametric models with intellectual disability and health need status treated as age-varying covariates (and an interaction term fitted). Knots were placed according to the event distribution in the intellectual disability group for greater statistical precision. All models used 5 knots (including the boundary knots; 4 degrees of freedom (df); 3df for age-varying effects) with the exception of PEG feeding, which used 4 knots (3df; 2df for age-varying effects) owing to the small sample size.

3. Results

3.1. Baseline Characteristics

Table 1 shows the characteristics of the study population over the observation period. The characteristics of the population with each individual health need are shown in Supplementary Table S3. In comparison to the rest of the population, people with intellectual disabilities were generally younger (median age 33 vs. 43 years) and more were male (57.1% vs. 49.0%). There were also more white individuals (77.0% vs. 67.5%), although this partly reflects more complete recording of ethnicity in hospital settings (only 14.0% vs. 19.6% had missing data because more people with LD were hospitalised and had their ethnicity recorded). Most individuals (73.4%) with intellectual disabilities had no cause identified: the most common genetic/chromosomal condition reported was Down syndrome (10.9% of the individuals). People with intellectual disabilities had a substantially higher proportion of all of the health needs under investigation compared to those without intellectual disabilities, as is reflected in the greater proportion without any health needs at baseline and follow-up (53.6% vs. 90.3%; intellectual disability vs. no intellectual disability).

The largest differences between people with and without intellectual disabilities were observed for cerebral palsy, which was ≈58 times more prevalent during the 2.7-year observation window (i.e., at baseline or follow-up). Epilepsy, severe visual loss, severe mobility difficulties and PEG feeding were ≈12–22 times more prevalent; and incontinence and severe health impairment were ≈2–4 times more prevalent. The most common severe health need in people with intellectual disabilities was epilepsy, which was present in 18.7% of
the individuals at baseline. For people without intellectual disabilities, incontinence was the most common health need, present in 3.8% of the individuals at baseline.

Table 1. Baseline and follow-up characteristics of the study population by intellectual disability and health need status.

| Characteristic                              | Intellectual Disability | No Intellectual Disability |
|---------------------------------------------|-------------------------|---------------------------|
|                                             | Number/ Median          | Percent/ Range            | Number/ Median          | Percent/ Range            |
| Total                                       | 7794                    | 100.0                     | 176,807                   | 100.0                     |
| Demographic characteristics                 |                         |                           |                           |                           |
| Age (years)                                 | 33.0                    | 10–101                    | 43.0                      | 10–108                    |
| Gender                                       |                          |                           |                           |                           |
| Male                                         | 4448                    | 57.1                      | 86,669                    | 49.0                      |
| Female                                       | 3346                    | 42.9                      | 90,138                    | 51.0                      |
| Ethnicity                                    |                          |                           |                           |                           |
| White                                        | 6002                    | 77.0                      | 119,403                   | 67.5                      |
| South Asian                                  | 211                     | 2.7                       | 7662                      | 4.3                       |
| Black                                        | 207                     | 2.7                       | 6236                      | 3.5                       |
| Other                                        | 280                     | 3.6                       | 8907                      | 5.0                       |
| Not known                                    | 1094                    | 14.0                      | 34,599                    | 19.6                      |
| Observation period                           |                         |                           |                           |                           |
| Length in cohort (years)                     | 1.5                     | >0.0–2.7                  | 1.9                       | >0.0–2.7                  |
| Most common genetic/chromosomal syndromes    |                         |                           |                           |                           |
| Down syndrome                                | 848                     | 10.9                      | -                         |                           |
| Fragile X syndrome                           | 151                     | 1.9                       | -                         |                           |
| Tuberous sclerosis                           | 60                      | 0.8                       | -                         |                           |
| Edward syndrome                              | 29                      | 0.4                       | -                         |                           |
| Prader–Willi syndrome                        | 27                      | 0.3                       | -                         |                           |
| Severe health needs                          |                          |                           |                           |                           |
| None (at baseline or follow-up)              | 4174                    | 53.6                      | 159,716                   | 90.3                      |
| Epilepsy                                     | Baseline                | 1456                      | 18.7                      | 2004                      | 1.1                       |
|                                             | during follow-up        | 55                       | 0.7                       | 201                       | 0.1                       |
| Incontinence                                 | Baseline                | 1039                      | 13.3                      | 6649                      | 3.8                       |
|                                             | during follow-up        | 214                      | 2.7                       | 1177                      | 0.7                       |
| Severe visual loss                           | Baseline                | 1015                      | 13.0                      | 1075                      | 0.6                       |
|                                             | during follow-up        | 227                      | 2.9                       | 204                       | 0.1                       |
| Severe hearing impairment                    | Baseline                | 551                       | 7.1                       | 5253                      | 3.0                       |
|                                             | during follow-up        | 67                       | 0.9                       | 592                       | 0.3                       |
| Severe mobility difficulties                 | Baseline                | 818                       | 10.5                      | 1280                      | 0.7                       |
|                                             | during follow-up        | 174                      | 2.2                       | 570                       | 0.3                       |
| Cerebral palsy                               | Baseline                | 658                       | 8.4                       | 261                       | 0.1                       |
|                                             | during follow-up        | 20                       | 0.3                       | 6                         | <0.1                      |
| PEG feeding                                  | Baseline                | 132                       | 1.7                       | 180                       | 0.1                       |
|                                             | during follow-up        | 20                       | 0.3                       | 54                        | <0.1                      |

1 n = 440 individuals moved from no intellectual disability to intellectual disability sample at first diagnosis during observation window. 2 n = 831 (10.7%) with phenylketonuria (not defined as a specific syndrome for this study). 3 PEG: percutaneous endoscopic gastrostomy.

3.2. Life Expectancy

Figure 1a–g shows the life expectancy estimates and percentage of life years lost (compared with the general population without health needs), for the severe health needs under investigation, by presence/absence of the health need and intellectual disability status. The final figure (Figure 1h) shows the life expectancy estimates for people without any of the health needs under investigation. Table 2 also presents the exact life expectancy estimates (with 95% CI) at 10, 20 and 40 years old.
Figure 1. (a–h) Life expectancy from 10 years of age by presence/absence of intellectual disability and health needs.
Perhaps the most striking finding from the figures is that life expectancy was substantially higher across the board in people with neither intellectual disabilities nor specified health need. At 10 years of age, these individuals could expect to live between 72.2 (absence of severe health impairment) and 74.3 additional years (all of the health needs absent). At the same age, children with intellectual disabilities but without each specified health need lost $\approx 15\text{–}22\%$ of life years compared to this first group, living, on average, an additional 57–62 years. Those with intellectual disabilities but without any of the health needs under investigation needs lost $\approx 12\%$ of life years, living on average 8.9 years shorter than those with neither intellectual disabilities nor health needs.

We can see that the most severe of the health needs, regardless of intellectual disability status, were PEG feeding and severe mobility difficulties. Ten-year-old children with a PEG feeding tube could expect to live only an additional 23.0 years (95% CI 17.1–31.0) if they had intellectual disabilities and 25.7 years (95% CI 18.3–36.0) if they did not have intellectual disabilities, representing a loss in life years of $\approx 65\text{–}68\%$ compared to those with neither condition. Similarly, children with severe mobility difficulties lost $\approx 41\text{–}44\%$ of life years, living an additional 41–43 years only compared to the almost 73 years in those with neither condition. The disadvantages for individuals with PEG feeding tubes and severe mobility difficulties continued to be observed in adulthood (Table 2).

Table 2. Additional years expected to live at age 10, 20 and 40 years by individual health need status and absence of health needs.

| Health Need Present | Health Need Absent | Health Need Present | Health Need Absent |
|---------------------|--------------------|---------------------|--------------------|
| Intellectual Disability | No Intellectual Disability | (11,631 Person-Years) | (296,324 Person-Years) |

**Epilepsy:** Additional years expected to live (95% CI): % life years lost

| Age | Epilepsy: Additional years expected to live (95% CI): % life years lost $^1$ |
|-----|--------------------------------------------------------------------------------|
| At 10 years: | 45.3 (40.5–50.7) 37.7% 61.5 (59.2–63.9) 15.4% 54.2 (50.0–58.9) 25.4% 72.7 (72.3–73.1) |
| At 20 years: | 38.0 (34.2–42.1) 39.3% 51.7 (49.4–54.0) 17.5% 46.8 (43.4–50.4) 25.4% 62.8 (62.4–63.2) |
| At 40 years: | 22.6 (20.0–25.6) 47.7% 33.0 (31.0–35.1) 23.8% 29.3 (26.8–32.0) 32.3% 43.2 (42.9–43.6) |

**Incontinence:** Additional years expected to live (95% CI): % life years lost

| Age | Incontinence: Additional years expected to live (95% CI): % life years lost $^1$ |
|-----|--------------------------------------------------------------------------------|
| At 10 years: | 48.6 (44.2–53.5) 33.6% 60.1 (57.5–62.8) 17.9% 64.1 (62.3–65.9) 12.4% 73.2 (72.8–73.7) |
| At 20 years: | 39.5 (35.5–43.9) 37.3% 50.8 (48.4–53.4) 19.6% 54.3 (52.5–56.0) 14.2% 63.3 (62.9–63.8) |
| At 40 years: | 23.2 (20.4–26.3) 47.2% 32.8 (30.6–35.1) 25.2% 35.3 (33.9–36.8) 19.4% 43.8 (43.4–44.2) |

**Severe visual loss:** Additional years expected to live (95% CI): % life years lost

| Age | Severe visual loss: Additional years expected to live (95% CI): % life years lost $^1$ |
|-----|--------------------------------------------------------------------------------|
| At 10 years: | 47.6 (39.2–57.9) 34.3% 58.5 (56.2–60.9) 19.3% 59.8 (53.9–66.3) 17.5% 72.5 (72.1–73.0) |
| At 20 years: | 42.1 (37.1–47.8) 32.8% 49.0 (46.4–51.3) 21.5% 51.6 (46.9–56.8) 17.6% 62.7 (62.3–63.0) |
| At 40 years: | 27.6 (24.2–31.5) 36.0% 30.7 (28.8–32.7) 28.9% 34.7 (31.5–38.3) 19.5% 43.1 (42.8–43.5) |

**Severe hearing impairment:** Additional years expected to live (95% CI): % life years lost

| Age | Severe hearing impairment: Additional years expected to live (95% CI): % life years lost $^1$ |
|-----|--------------------------------------------------------------------------------|
| At 10 years: | 60.3 (54.4–66.8) 16.5% 56.7 (54.4–59.1) 21.5% 73.8 (72.2–75.4) $^2$ 22.2% 72.2 (71.8–72.6) |
| At 20 years: | 50.3 (44.5–56.9) 19.0% 47.5 (45.4–49.7) 23.5% 63.8 (62.2–65.4) $^2$ 24.2% 62.3 (61.9–62.7) |
| At 40 years: | 31.1 (25.8–37.4) 27.5% 29.7 (27.9–31.6) 30.6% 44.0 (42.5–45.5) $^2$ 27.2% 42.8 (42.5–43.2) |
Table 2. Cont.

| Health Need Present | Intellectual Disability (11,631 Person-Years) | No Intellectual Disability (296,324 Person-Years) |
|---------------------|---------------------------------------------|-------------------------------------------------|
| Epilepsy            | Additional years expected to live (95% CI): % life years lost 1 |                                  |
| At 10 years         | 40.9 (35.0–47.8) 44.4% 61.8 (59.4–64.3) 15.9% 43.1 (37.7–49.3) 41.4% 73.5 (73.0–73.9) 15.9% 64.7 (64.3–65.0) 73.5 (73.0–73.9) |
| At 20 years         | 33.2 (28.8–38.3) 47.4% 52.3 (50.0–54.7) 17.5% 34.7 (30.5–39.6) 44.9% 63.6 (63.2–64.0) 17.5% 58.7 (58.3–64.0) 63.6 (63.2–64.0) |
| At 40 years         | 18.8 (16.2–21.7) 57.4% 34.0 (32.0–36.1) 22.8% 18.9 (16.5–21.7) 57.0% 44.1 (43.7–44.4) 22.8% 35.1 (34.7–35.0) 44.1 (43.7–44.4) |
| Severe mobility difficulties: Additional years expected to live (95% CI): % life years lost 1 |
| At 10 years         | 41.5 (33.3–51.7) 42.6% 59.3 (57.2–61.4) 18.0% 69.2 (52.2–91.9) 4.3% 72.3 (71.9–72.7) 18.0% 69.7 (69.5–70.0) 72.3 (71.9–72.7) |
| At 20 years         | 35.0 (28.0–43.8) 44.0% 49.6 (47.6–51.6) 20.3% 60.6 (44.6–82.3) 3.2% 62.5 (62.1–62.8) 20.3% 59.9 (59.5–60.3) 62.5 (62.1–62.8) |
| At 40 years         | 25.8 (19.9–33.3) 40.0% 30.7 (28.9–32.5) 28.6% 44.9 (32.4–62.3) −4.7% 42.9 (42.6–43.3) 28.6% 38.5 (38.2–38.8) 42.9 (42.6–43.3) |
| Cerebral palsy: Additional years expected to live (95% CI): % life years lost 1 |
| At 10 years         | 23.0 (17.1–31.0) 68.3% 58.3 (56.2–60.5) 19.6% 25.7 (18.3–36.0) 64.6% 72.5 (72.1–72.9) 19.6% 51.6 (51.3–51.9) 72.5 (72.1–72.9) |
| At 20 years         | 14.0 (9.0–22.0) 76.8% 48.6 (46.6–50.7) 22.2% 17.1 (11.0–26.6) 72.0% 62.6 (62.3–63.0) 22.2% 38.7 (38.4–39.0) 62.6 (62.3–63.0) |
| At 40 years         | 8.5 (4.0–18.2) 80.2% 30.9 (29.2–32.7) 28.3% 9.9 (6.0–16.3) 77.0% 43.1 (42.8–43.5) 28.3% 17.5 (17.2–18.0) 43.1 (42.8–43.5) |

None of the health needs: Additional years expected to live (95% CI): % life years lost 1

1 Percentage of life years lost compared with people with neither intellectual disability nor the specified health need. 2 PEG: Percutaneous endoscopic gastrostomy.

4. Discussion

This work deepens our understanding of health inequalities in people with intellectual disabilities. By reaffirming that severe health needs make a significant contribution to the mortality disparities that people with intellectual disabilities are known to experience, our findings also reveal that they only partially explain these. After restricting the study population to those without health needs, life expectancy remained shorter for those with intellectual disabilities, with a loss in life years of 12%. Of those with the specified health needs, life expectancy was generally further shortened if intellectual disability was also present, suggesting combined disadvantages.

4.1. Strengths and Limitations

To the best of our knowledge, this is the first time that life expectancy has been explored by health needs in people with and without intellectual disabilities. By reaffirming that severe health needs make a significant contribution to the mortality disparities that people with intellectual disabilities are known to experience, our findings also reveal that they only partially explain these. After restricting the study population to those without health needs, life expectancy remained shorter for those with intellectual disabilities, with a loss in life years of 12%. Of those with the specified health needs, life expectancy was generally further shortened if intellectual disability was also present, suggesting combined disadvantages.

As with all electronic health record data of this nature which rely on Read code and ICD diagnoses, we are unable to capture variability in the severity of health needs between people with intellectual disabilities and the general population. A particular concern is incontinence, which is likely to be less severe in the general population if it occurred and was resolved during certain life events, such as post-pregnancy [25]; it is noteworthy that almost three-quarters (73.3%) of the people in the general population with incontinence were female, compared with only half (53.2%) in the intellectual disability
population (Supplementary Table S3). Moreover, both incontinence and PEG feeding may be indicative of additional comorbidities (e.g., frailty or dysphagia) rather than directly causing mortality [26,27]. Our findings nonetheless support their relationship (even if indirect) with life expectancy. Another limitation of GP health record data is that they do not provide complete information on the severity of intellectual disabilities; we are also likely to have missed people with mild intellectual disabilities who do not have significant support needs and may also be more vulnerable to abuse, discrimination and high-risk behaviours. We also recognise that many of these health needs co-occur and that they are more likely to do so if the individual also has intellectual disabilities, as is reflected in the larger proportion of individuals with at least one health need (46% vs. 10%) and high prevalence of co-occurring health needs, particularly for individuals with cerebral palsy (53% of individuals with intellectual disabilities also had epilepsy; 56% had severe mobility difficulties) and PEG feeding tubes (55% had cerebral palsy; 65% epilepsy and 70% severe mobility difficulties) (Table S3). This descriptive study does not look in more depth at the co-occurring health needs, nor does it adjust for additional clinically relevant comorbidities, such as dementia, or other social determinants of health which all contribute to the mortality disadvantages that people with intellectual disabilities experience [28]. Such issues could be explored further using propensity score methodologies or multiple logistic regression/time-to-event analyses, which are recommended to further develop the work described here.

This study took place before the COVID-19 pandemic, during which people with intellectual disabilities have been adversely affected owing to increased risk of transmission (e.g., through residential homes and community-based support) and increased risk of respiratory deaths [29–31]. People with severe health needs have also been disproportionately affected by COVID-19 [32]. In the current climate, the recommendations made here are, therefore, likely to be more relevant.

4.2. Comparison with Existing Literature

The prevalence of severe health needs found at baseline in this study is largely similar to that found in previous research carried out in the UK and internationally. The prevalence of epilepsy was 18.7% (vs. 1.1% in the general population), which corresponds with previous population-based studies from England (18.5% vs. 0.7% (matched age/gender/practice population sample) [19]) and Scotland (18.8% vs. 0.8% [10]). The prevalence of incontinence in the intellectual disability population (13.3%) was lower than previous UK estimates using the CPRD (20.5% [19]), which we attribute to the exclusion of ‘H/O incontinence’ and incontinence diagnoses within 10 years of cohort entry for the current study. The baseline prevalence of 3.8% found in the general population is at the lower end of the estimates of international figures of 3–18% for severe incontinence (urinary only) in adult women (about half of this for men) [33], given that many do not seek support from a healthcare provider [34]. The prevalence of PEG feeding (1.9% vs. 0.1%) also falls within the 5-year incidence rate (1.3%) of PEG procedures in England based on 17,000 per year [35].

In our study, prevalence of severe visual impairment among people with intellectual disabilities (13.0%) was lower than previous estimates in the Netherlands for visual impairment and blindness (13.8% and 5.0%, respectively) but, of the latter population, 40.6% were undiagnosed prior to study commencement [36]. We did not find a relationship between severe hearing impairment and life expectancy, which differs from previous (albeit not statistically significant) work in the general population [37].

The prevalence of cerebral palsy we reported here (8.4% vs. 0.1%) can be interpreted using information from the random general population sample. Given that this sample was drawn from 6.2 million individuals (Supplementary Figure S1) and that 0.5% of the general population sample had intellectual disabilities, and assuming a representative random sample draw, the prevalence of cerebral palsy in our study was approximately 1.42 per 1000 population, which is similar to birth estimates reported of 2.11 per 1000 population [38] conditional on surviving to 10 years. We would also expect there to be 2276 (i.e., 6.2 times
as many) people with cerebral palsy in the entire population sample, which would equate to 29% of people with cerebral palsy having intellectual disabilities. This is within the range reported in the literature, which cites 22–40% of individuals with cerebral palsy having cognitive impairment (IQ < 70) [39], although some studies report figures closer to one-half [40]. It is worth emphasising, however, that many—if not most—people with cerebral palsy do not have intellectual disabilities and it is important to make sure that their needs are adequately met. The prevalence of severe mobility difficulties (10.5%) in people with intellectual disabilities is similar to previous estimates of 9.2% for being ‘non-mobile’ [41], but it is hard to determine the prevalence in the general population owing to the recognised variation in thresholds for reporting mobility disabilities [42].

4.3. Recommendations

Given that this descriptive study did not seek to control for other contributing factors, we are nonetheless able to make some broad recommendations. First, it is clear from our findings that health needs are a significant problem for people with intellectual disabilities and that, with the exception of severe hearing impairments, they play a key role in shortening life expectancy. More effective management and treatment of these health needs, including regular assessment of associated care requirements, have the potential to improve outcomes and quality of life for those affected. Many of these health needs are relatively rare in the general population, so the development of tailored care pathways for people with intellectual disabilities, based on national guidelines and policies where available, is likely to be a priority. Such pathways may include monitoring medication (e.g., epilepsy—with a focus on epilepsy syndromes and tuberous sclerosis), provision of specialist support (e.g., visual impairment and hearing impairment), communication plans (e.g., cerebral palsy), pain management (e.g., severe mobility difficulties), prevention strategies (e.g., incontinence) and oral care (e.g., PEG feeding). All pathways should include mechanisms for the provision of coordinated care between health, social care and voluntary services so that unnecessary burden is not placed on carers. They should also be adequately flexible to allow for individuals’ differences and needs.

5. Conclusions

We conclude that differential life expectancy in people living with intellectual disabilities compared to the general population is not wholly attributable to increased prevalence of severe health needs. Our findings highlight the need to continue to find ways to improve health outcomes and quality of life for people living with intellectual disabilities so that they can be supported to lead long and fulfilling lives.

Supplementary Materials: The following supplementary information can be downloaded at https://www.mdpi.com/article/10.3390/ijerph19116602/s1, Table S1: RECORD checklist; Table S2: Diagnostic and classification codes for intellectual disabilities, ethnicity and severe health needs investigated; Figure S1: Data flow diagram of individuals included in the study population from original extracted data; Table S3: Characteristics of individuals with specific health needs under investigation.

Author Contributions: Conceptualisation, F.T. and M.J.R.; data curation, F.T. and M.J.R.; methodology, F.T., M.J.R., R.M., R.K. and S.K.G.; validation, M.J.R.; formal analysis, F.T.; investigation, F.T., M.J.R., R.M., R.K., H.K. and S.K.G.; resources, F.T. and M.J.R.; writing—original draft preparation, F.T.; writing—review and editing, F.T., M.J.R., R.M., R.K., H.K. and S.K.G.; visualisation, F.T. and M.J.R.; supervision, M.J.R. and R.M.; project administration, F.T. and M.J.R.; funding acquisition, F.T. and M.J.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded from a Baily Thomas Doctoral Fellowship award (TRUST/VC/AC/SG/5366-8393). The funders had no role in study design, data collection and analysis, the decision to publish or the preparation of the manuscript. The study is based in part on data from the CPRD GOLD database obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The provision of CPRD and linked data was through Leicester Real World Evidence (LRWE) Unit, which is funded by University of Leicester, National Institute for Health Research (NIHR)
Applied Research Collaboration (ARC) East Midlands and Leicester NIHR Biomedical Research Centre. The interpretation and conclusions contained in this article are those of the authors alone and not necessarily those of the LRWE Unit, the NHS, the NIHR or the Department of Health and Social Care.

**Institutional Review Board Statement:** The CPRD has Health Research Authority (HRA) approval for all studies using anonymised data for observational research (East Midlands Research Ethics Committee [REC] No. 05/MRE04/87). Research using the CPRD is also subject to regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) Independent Scientific Advisory Committee (ISAC); the approved protocol reference no. for this study is: 19/267RA3.

**Informed Consent Statement:** The CPRD has Health Research Authority (HRA) approval for all studies using anonymised data for observational research (East Midlands Research Ethics Committee [REC] No. 05/MRE04/87). Consent was not obtained for the use of anonymised data—approval for the use of the CPRD (data controller) was through the UK MHRA Independent Scientific Advisory Committee (ISAC) (approved protocol no. 19/267RA3).

**Data Availability Statement:** Data for this study were obtained from the Clinical Practice Research Datalink (CPRD), provided by the UK MRHA. The authors’ licence for using these data does not allow sharing of raw data with third parties. Information about access to CPRD data is available here: https://www.cprd.com/research-applications (accessed on 20 May 2022). Researchers should contact the ISAC Secretariat at isac@cprd.com for further details.

**Acknowledgments:** The authors gratefully acknowledge support from people with intellectual disabilities and their family carers for relating their own health-related experiences, health needs and support that they received with their health and social care. In particular, we would like to thank: the Talk & Listen group (Leicester, UK), ably facilitated by Pauline Ndigirwa; the Charnwood Action Group (Leicestershire, UK); Gill Huddleston (Carers’ UK); Sarah Stanyer; Amy Stanway and Kate Dolan.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. World Health Organization Commission on Social Determinants of Health. Closing the Gap in a Generation: Health Equity through Action on the Social Determinants of Health. 2008. Available online: https://www.who.int/social_determinants/thecommission/finalreport/en/ (accessed on 22 April 2021).

2. United Nations General Assembly. Political Declaration of the High-Level Meeting on Universal Health Coverage: “Universal Health Coverage: Moving Together to Build a Healthier World” [A/RES/74/]. 2019. Available online: https://www.un.org/en/ga/74/resolutions.shtml (accessed on 22 April 2021).

3. Department of Health and Social Care. Advancing Our Health: Prevention in the 2020s—Consultation Document. 2019. Available online: https://www.gov.uk/government/consultations/advancing-our-health-prevention-in-the-2020s/advancing-our-health-prevention-in-the-2020s-consultation-document (accessed on 27 July 2020).

4. European Commission. The European Pillar of Social Rights in 20 Principles. 2017. Available online: https://ec.europa.eu/info/sites/default/files/social-summit-european-pillar-social-rights-booklet_en.pdf (accessed on 2 December 2021).

5. European Commission. Union of Equality. Strategy for the Rights of Persons with Disabilities 2021–2030. 2021. Available online: https://ec.europa.eu/social/BlobServlet?docId=23707&langId=en (accessed on 30 November 2021).

6. Office of Disease Prevention and Health Promotion; U.S. Department of Health and Human Services. Secretary’s Advisory Committee for Healthy People 2030. Report 7: Reviewing and Assessing the Set of Proposed Objectives for Healthy People 2030. 2019. Available online: https://www.healthypeople.gov/sites/default/files/Report%207_Reviewing%20Assessing%20Objectives_Formatted%20EO_508_05.21.pdf (accessed on 30 November 2021).

7. World Health Organization Regional Office for Europe. Better Health, Better Lives: Research Priorities. 2012. Available online: https://apps.who.int/iris/handle/10665/107303 (accessed on 3 December 2021).

8. Australian Civil Society CRPD Shadow Report Working Group. Disability Rights Now. Australian Civil Society Shadow Report to the United Nations Committee on the Rights of Persons with Disabilities: UN CRPD Review. 2019. Available online: https://tbinternet.ohchr.org/Treaties/CRPD/Shared%20Documents/AUS/INT_CRPD_CSS_AUS_35639_E.pdf (accessed on 14 January 2022).

9. Emerson, E.; Hatton, C. Health Inequalities and People with Intellectual Disabilities; Cambridge University Press: Cambridge, UK, 2014.

10. Cooper, S.-A.; McLean, G.; Guthrie, B.; McConnachie, A.; Mercer, S.; Sullivan, F.; Morrison, J. Multiple physical and mental health comorbidity in adults with intellectual disabilities: Population-based cross-sectional analysis. *BMC Fam. Pract.* 2015, 16, 110. [CrossRef] [PubMed]
11. Robertson, J.; Hatton, C.; Emerson, E.; Baines, S. The impact of health checks for people with intellectual disabilities: An updated systematic review of evidence. *Res. Dev. Disabil.* 2014, 35, 2450–2462. [CrossRef] [PubMed]
12. Tyrer, F.; Morriss, R.; Kiani, R.; Gangadharan, S.K.; Rutherford, M.J. Mortality disparities and deprivation among people with intellectual disabilities in England: 2000–2019. *J. Epidemiol. Community Health* 2022, 76, 168–174. [CrossRef] [PubMed]
13. Heslop, P.; Blair, P.; Fleming, P.; Hoghton, M.; Marriott, A.; Russ, L. Confidential Inquiry into Premature Deaths of People with Learning Disabilities (CiPOLD). Norah Fry Research Centre, University of Bristol. 2013. Available online: http://www.bristol.ac.uk/medicine-library/sites/cipold/migrated/documents/fullfinalreport.pdf (accessed on 14 January 2022).
14. Trollor, J.; Srasuebkul, P.; Xu, H.; Howlett, S. Cause of death and potentially avoidable deaths in Australian adults with intellectual disability using retrospective linked data. *BMJ Open* 2017, 7, e013489. [CrossRef]
15. Carey, I.M.; Hosking, F.J.; Harris, T.; De Wilde, S.; Beighton, C.; Cook, D.G. An evaluation of the effectiveness of annual health checks and quality of health care for adults with intellectual disability: An observational study using a primary care database. *NIHR J. Libr.* 2017, 9, 9. [CrossRef]
16. Benchimol, E.I.; Smeeth, L.; Guttmann, A.; Harron, K.; Moher, D.; Petersen, I.; Sørensen, H.T.; von Elm, E.; Langan, S.M. The Reporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS Med.* 2015, 12, e1001885. [CrossRef]
17. Herrett, E.; Gallagher, A.M.; Bhaskaran, K.; Forbes, H.; Mathur, R.; van Staa, T.; Smeeth, L. Data resource profile: Clinical Practice Research DataLink (CPRD). *Int. J. Epidemiol.* 2015, 44, 827–836. [CrossRef]
18. Florio, T.; Trollor, J. Mortality among a cohort of persons with an intellectual disability in New South Wales, Australia. *J. Appl. Res. Intell. Disabil.* 2015, 28, 383–393. [CrossRef]
19. Carey, I.M.; Shah, S.M.; Hosking, F.J.; De Wilde, S.; Harris, T.; Beighton, C.; Cook, D.G. Health characteristics and consultation patterns of people with intellectual disability: A cross-sectional database study in English general practice. *Br. J. Gen. Pract.* 2016, 66, e264. [CrossRef]
20. Aaberg, K.M.; Gunnes, N.; Bakken, I.J.; Lund Søraas, C.; Berntsen, A.; Magnus, P.; Lossius, M.I.; Stoltenberg, C.; Chin, R.; Surén, P. Incidence and Prevalence of Childhood Epilepsy: A Nationwide Cohort Study. *Pediatrics* 2017, 139, e20163908. [CrossRef]
21. National Institute for Health and Care Excellence (NICE). Epilepsies: Diagnosis and Management, Clinical Guideline [CG137] [updated May 2021] 2021. Available online: https://www.nice.org.uk/guidance/cg137 (accessed on 18 March 2022).
22. Blair, E.; Langdon, K.; McIntyre, S.; Watson, L. Survival and mortality in cerebral palsy: Observations to the sixth decade from a data linkage study of a total population register and National Death Index. *BMJ Neurol.* 2019, 19, 111. [CrossRef] [PubMed]
23. Tyrer, F.; Bhaskaran, K.; Rutherford, M.J. Immortal time bias for life-long conditions in retrospective observational studies using electronic health records. *BMC Med. Res. Methodol.* 2022, 22, 86. [CrossRef] [PubMed]
24. Tyrer, F.; Chudasama, Y.; Lambert, P.C.; Rutherford, M.J. Flexible Parametric Methods for Calculating Life Expectancy in Small Populations. 2022; under review.
25. Chang, S.-R.; Lin, W.-A.; Lin, H.-H.; Lee, C.-N.; Chang, T.-C.; Lin, M.-I. Cumulative incidence of urinary incontinence and associated factors during pregnancy and after childbirth: A cohort study. *Int. Urogynecology J.* 2021. (online ahead of print). [CrossRef] [PubMed]
26. Matta, R.; Hird, A.E.; Sasaki, R.; Radomska, S.B.; Carr, L.; Kodama, R.T.; Nam, R.K.; Herschorn, S. Is There an Association between Urinary Incontinence and Mortality? A Retrospective Cohort Study. *J. Urol.* 2020, 203, 591–597. [CrossRef] [PubMed]
27. Becker, R.; Nieczaj, R.; Egge, K.; Moll, A.; Meinhardt, M.; Schulz, R.J. Functional dysphagia therapy and PEG treatment in a clinical geriatric setting. *Dysphagia* 2011, 26, 108–116. [CrossRef]
28. Tyrer, F.; Kiani, R.; Rutherford, M.J. Mortality, predictors and causes among people with intellectual disabilities: A systematic narrative review supplemented by machine learning. *J. Intellect. Dev. Disabil.* 2021, 46, 102–114. [CrossRef]
29. Glasson, E.J.; Jacques, A.; Wong, K.; Bourke, J.; Leonard, H. Improved survival in Down syndrome over the last 60 years and the impact of perinatal Factors in recent decades. *J. Pediatrics* 2016, 169, 214–220. [CrossRef]
30. Day, S.M.; Wu, Y.W.; Strauss, D.J.; Shavellle, R.M.; Reynolds, R.J. Causes of death in remote symptomatic epilepsy. *Neurology* 2005, 65, 216–222. [CrossRef]
31. Public Health England. *COVID-19 Deaths of People Identified as Having Learning Disabilities: Report*; Public Health England: London, UK, 2020. Available online: https://www.gov.uk/government/publications/covid-19-deaths-of-people-with-learning-disabilities/covid-19-deaths-of-people-identified-as-having-learning-disabilities-summary (accessed on 23 February 2021).
32. Read, J.M.; Green, C.A.; Harrison, E.M.; Docherty, A.B.; Funk, S.; Harrison, J.; Girvan, M.; Hardwick, H.E.; Turtle, L.; Dunning, J.; et al. Hospital-acquired SARS-CoV-2 infection in the UK’s first COVID-19 pandemic wave. *Lancet* 2021, 398, 1037–1038. [CrossRef]
33. Hunskaar, S.; Arnold, E.P.; Burgio, K.; Diokno, A.C.; Herzog, A.R.; Mallett, V.T. Epidemiology and natural history of urinary incontinence. *Int. Urogynecology J. Pelvic Floor Dysfunct.* 2000, 11, 301–319. [CrossRef]
34. Duralde, E.R.; Walter, L.C.; Van Den Eeden, S.K.; Nakagawa, S.; Subak, L.L.; Brown, J.S.; Thom, D.H.; Huang, A.J. Bridging the gap: Determinants of undiagnosed or untreated urinary incontinence in women. *Am. J. Obstet. Gynecol.* 2016, 214, e261–e266. [CrossRef] [PubMed]
35. Sanders, D.S.; Carter, M.J.; D'Silva, J.; James, G.; Bolton, R.P.; Willemse, P.J.; Bardhan, K.D. Percutaneous endoscopic gastrostomy: A prospective audit of the impact of guidelines in two district general hospitals in the United Kingdom. *Am. J. Gastroenterol.* 2002, 97, 2239–2245. [CrossRef] [PubMed]

36. van Splunder, J.; Stilma, J.S.; Bernsen, R.M.; Evenhuis, H.M. Prevalence of visual impairment in adults with intellectual disabilities in the Netherlands: Cross-sectional study. *Eye* 2006, 20, 1004–1010. [CrossRef] [PubMed]

37. Contrera, K.J.; Betz, J.; Genthier, D.J.; Lin, F.R. Association of Hearing Impairment and Mortality in the National Health and Nutrition Examination Survey. *JAMA Otolaryngol. Head Neck Surg.* 2015, 141, 944–946. [CrossRef] [PubMed]

38. Oskoui, M.; Coutinho, F.; Dykeman, J.; Jetté, N.; Pringsheim, T. An update on the prevalence of cerebral palsy: A systematic review and meta-analysis. *Dev. Med. Child Neurol.* 2013, 55, 509–519. [CrossRef] [PubMed]

39. Odding, E.; Roebroeck, M.E.; Stam, H.J. The epidemiology of cerebral palsy: Incidence, impairments and risk factors. *Disabil. Rehabil.* 2006, 28, 183–191. [CrossRef] [PubMed]

40. Reid, S.M.; Meehan, E.M.; Arnup, S.J.; Reddihough, D.S. Intellectual disability in cerebral palsy: A population-based retrospective study. *Dev. Med. Child Neurol.* 2018, 60, 687–694. [CrossRef]

41. Tyrer, F.; Ling, S.; Bhaumik, S.; Gangadharan, S.K.; Khunti, K.; Gray, L.J.; Dunkley, A.J. Diabetes in adults with intellectual disability: Prevalence and associated demographic, lifestyle, independence and health factors. *J. Intellect. Disabil. Res.* 2020, 64, 287–295. [CrossRef]

42. Melzer, D.; Lan, T.-Y.; Tom, B.D.M.; Deeg, D.J.H.; Guralnik, J.M. Variation in Thresholds for Reporting Mobility Disability Between National Population Subgroups and Studies. *J. Gerontol. Ser. A* 2004, 59, 1295–1303. [CrossRef]